Minimally Invasive Ablative Therapies for Definitive Treatment of Localized Prostate Cancer in the Primary Setting by Lee, Eugene W. & Huang, William C.
Hindawi Publishing Corporation
Prostate Cancer
Volume 2011, Article ID 394182, 7 pages
doi:10.1155/2011/394182
Review Article
MinimallyInvasiveAblativeTherapies forDeﬁnitiveTreatment of
LocalizedProstateCancerin thePrimary Setting
EugeneW.Lee andWilliamC.Huang
Department of Urology, New York University School of Medicine, NY 10016, USA
Correspondence should be addressed to Eugene W. Lee, eugene.lee@nyumc.org
Received 25 August 2010; Accepted 28 October 2010
Academic Editor: Michael Froehner
Copyright © 2011 E. W. Lee and W. C. Huang. This is an open access article distributed under the Creative CommonsAttribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Traditionally, the patient with a new diagnosis of localized prostate cancer faces either radical therapy, in the form of surgery or
radiation, or active surveillance. A growing subset of these men may not be willing to accept the psychological burden of active
s u r v e i l l a n c en o rt h es i d ee ﬀects of extirpative or radiation therapy. Local ablative therapies including cryotherapy, high-intensity
focused ultrasound, and vascular-targeted photodynamic therapy have emerged as a means for minimally invasive deﬁnitive
treatment. Thesetreatments arewell toleratedwithdecreased morbidityinassociationwithimprovementsintechnology; however,
long-term oncologic eﬃcacy remains to be determined.
1.Introduction
According to the recently updated 2007 AUA Guideline for
the Management of Clinically Localized Prostate Cancer, the
standard management for localized prostate cancer includes
radical therapy such as, prostatectomy or radiation therapy,
or active surveillance [1]. Routine use of PSA screening has
increased the number of relatively young men with low-
stage, low-risk disease, who may not be willing to accept the
potential side eﬀects of traditional deﬁnitive treatment [2].
Although active surveillance is an option, these men may be
unwilling to accept the psychological burden associated with
this approach. Furthermore, a recent study of postprostatec-
tomy patients meeting criteria for active surveillance showed
that a signiﬁcant number of these patients had higher-
risk disease on ﬁnal pathology with 17% BCR at 5 years
(deﬁned as 3 consecutive PSA rises with peak >0.15ng/dL)
[3]. As a result, the conventional choice between radical
therapy and active surveillance is not palatable for a growing
subset of men diagnosed with clinically localized prostate
cancer, and this has led to a greater interest in less invasive
therapies that may provide cancer control with potentially
decreased morbidity. Minimally invasive ablative therapies
employ a variety of energy sources to ablate prostate tissue in
the outpatient setting, using advanced imaging technology
and protective devices to reduce treatment-related morbid-
ity. Cryotherapy, high-intensity focused ultrasound (HIFU),
and vascular-targeted photodynamic therapy (VTP) have all
been used in this setting as primary therapy with varying
degrees of experience.
2.Cryotherapy
Cryotherapy destroys prostate tissue by freezing cells down
to extremely low temperatures (−40◦C). Cryoprobes placed
under TRUS guidance mediate extraction of heat from the
prostate resulting in cell death via formation of intracellular
ice aswell as byinduction ofthe apoptosisand inﬂammatory
cascade [4]. A recent AUA Best Practice Statement describes
cryotherapy as a reasonable therapeutic option in both the
primary and salvage settings [5], and with a projected 15,000
procedures expected to be performed in USA in 2010 [6], it
isthe most widelyused ablativetherapywiththelargest body
of published data.
Cryotherapy is not a new tool for urologic oncologists—
the ﬁrst cryosurgical probe system using liquid nitrogen was
described in 1961 by Cooper and Lee [7] and was initially2 Prostate Cancer
used to treat benign prostatic hypertrophy by Gonder et al.
[8]. In 1972, Flocksreported using a perineal incision to per-
form cryosurgical ablation of prostate cancer [9]. However,
due to crude temperature-monitoring measures for ice ball
control (digital rectal guidance or direct vision), there were
high rates of rectourethral ﬁstulas, urinary incontinence,and
strictures. With the introduction of TRUS guidance by Onik
[10], the modern era of cryotherapy for prostate cancer was
initiated.Continuedtechnologicaladvancementsoversubse-
quentplatforms, includingthermocoupledevicestomonitor
temperature, urethral warming to prevent ﬁstula [11], argon
gas facilitating the use of small cryoprobes passable through
a brachytherapy grid [12], and the concurrent development
of more sophisticated imaging and computer software for
optimalprobeplacement,haveallcontributedtominimizing
the morbidity of the procedure.
3.SelectionCriteria
The recently published AUA Best Practice Statement on
Cryosurgery [5] states that cryotherapy is appropriate for
men with clinically organ-conﬁned disease of any grade
with a negative metastatic evaluation. Cryotherapy may be
best suited for men who do not wish to undergo radical
prostatectomy or radiation therapy due to side eﬀects or
because of comorbidities or conditions which make them
poor candidates for either conventional surgery or radiation.
Although clinical T3 disease has been treated in many
reports, there are limited outcomes data for this, and
therefore the role of cryotherapy in this setting remains
undetermined. Best results are seen with a PSA < 10ng/mL,
and patients with high-risk disease may require multimodal
therapy.Prostateglandvolumecanbealimitingfactor, asthe
gland must be encompassed within the ice ball. Therefore,
most reports limit prostate size to 40–60cc. Although it has
not been shown to improve cancer control, neoadjuvant
androgen deprivation therapy has been used to shrink the
gland to facilitate cryotherapy when a larger gland is present.
A history of TURP is a relative contraindication as these
patients are at increased risk of urethral sloughing.
4.Deﬁnitionof TreatmentSuccess
Cryotherapy has the largest body of literature of the
minimally invasive ablative therapies. However, there is a
lack of consensus on the deﬁnition of biochemical failure
for cryotherapy, and this is the greatest limitation in
deﬁning treatment success and drawing comparisons to
other treatment modalities. Published reports thus far have
used PSA cut-oﬀs from 0.1, 0.4, 0.5, and 1.0ng/mL as
well as the old ASTRO deﬁnition of 3 consecutive PSA
rises, with most recent studies adopting the new ASTRO
Phoenix criteria of nadir plus 2ng/mL [13–18]. However,
the Phoenix criteria authors speciﬁcally stated that it was
not to be used for cryotherapy [19]. On the other hand,
although cryotherapy technically ablates prostatic tissue, the
standard for radical prostatectomy may not be appropriate
because urethral warming technology invariably preserves
periurethralprostatictissue[20].Theappropriatecutoﬀlevel
to guide treatment remains to be determined. The Cryo On-
Line Data Registry (COLDregistry) is a multicenterdatabase
pooling data from both academic and community centers,
and the maturation of this large data set will hopefully
provide answers [21].
W h i l ew ec u r r e n t l yl a c ks u c hac u t o ﬀ value, it has been
demonstrated that the lower the PSA after cryosurgery,
the greater the likelihood that PSA will remain stable and
posttreatment biopsies negative (although the value of post-
treatmentbiopsyisquestionableduetotheeﬀectofsampling
error) [13, 22, 23]. In 2009, Levy applied the Phoenix criteria
to 2,427 men from the COLD registry to demonstrate that a
PSA nadir of 0.5 or less resulted in a favorable biochemical
disease-free survival (bDFS), especially for low-risk disease
[14].
5.Outcomes
Several series have greater than 5-year followup, reporting
bDFS rates using various deﬁnitions for success and with
results stratiﬁed according to D’Amico risk groupings. The
5-year bDFS rates range from 65% to 92% for low risk, 69%
to 89% for intermediate risk, and 45% to 89% for high-
risk disease [15–17, 21, 24]. The largest series is reported by
Jones et al. using 1,198 patients from the COLD registry. At
5 years, using Phoenix criteria, the bDFS was 91, 79, and 62
percent, respectively [21]. The series with longest followup
is reported by Cohen, who evaluated 204 patients with a
median followup of 12.55 years. Using Phoenix criteria,
bDFS was 81, 74, and 45 percent at 10 years [11]. Many of
the aforementioned studies have examined prostate biopsies
following primary cryotherapy. Negative biopsy rates range
from 87% to 93% [13, 15, 24].
In a recently published report, Donnelly et al. com-
pared primary cryotherapy with external beam radiation
in a randomized prospective trial of 244 patients designed
to show noninferiority (deﬁned as a 10% diﬀerence in
disease progression) [25]. Progression was based on a
trifecta deﬁnition including biochemical failure (deﬁned by
both Phoenix criteria as well as 2 consecutive rises with
ﬁnal value >1.0), radiologic evidence for metastases, and
initiation of additional prostate cancer therapy. Secondary
endpoints were overall and disease-speciﬁc survival and
prostate biopsy at 3 years. Patients had T2 or T3 disease
with the majority being either at high or intermediate risk,
andall122patientsreceivedneoadjuvanthormoneandrogen
deprivation therapy as per standard EBRT protocol, then
progressing to treatment in each arm. At a median of
84-month followup, biochemical failure rates were similar
with 27% in the cryotherapy arm versus 31.7% in the
EBRT arm (Phoenix criteria); however, noninferiority could
not be established because the small sample size resulted
in wide conﬁdence intervals. There was no diﬀerence in
overall or disease-speciﬁc survival at 5 years, and there were
signiﬁcantly less positive biopsies at 3 years for cryotherapy
(7.7% versus 28.9%). This must be interpreted cautiously
as the clinical importance of positive biopsy after EBRT isProstate Cancer 3
unknown [26]. It should also be noted that the trial protocol
was modiﬁed for the dose of neoadjuvant hormones from
3m o n t h st o6m o n t h s ,a sw e l la sr a d i a t i o nd o s ef r o m6 8
to 73.5Gy, reﬂecting changing standards of practice. This
may have an eﬀect on biochemical failure rates on longer
followup.
6.Complications
When cryotherapy of the prostate was originally introduced
in the 1960s, its use was limited and eventually abandoned
due to the high morbidity of the procedure, particularly the
high incidence of rectourethral ﬁstula. With its reintroduc-
tioninthe1990s,threegenerationsofimprovements,andthe
various technological advancements, the adverse side eﬀects
associated with the procedure signiﬁcantly decreased.
The most dreaded complication, rectourethral ﬁstula,
is no longer expected with 0%–0.5% incidence during
primary therapy, a rate similar to that seen for rectal injury
following radical prostatectomy or radiation therapy [15, 16,
24, 27]. The use of thermocouple technology to monitor
temperatures at the external sphincter has minimized rates
of urinary incontinence to 1%–8%, previously as high as
83% with earlier systems [18, 28–31]. The updated COLD
registry data presented in 2010 by Dhar et al. reported
3.1% incontinence at 12-months followup [32]. Urethral
sloughing is minimized with the urethral warming catheter,
and most series report rates from 1 to 15 percent, with
resolution after catheterization and TURP necessary in the
minority of cases [21].
Erectile dysfunction remains the major morbidity of
cryotherapy, and it continues to be common despite tech-
nological improvements. Despite some series reporting rates
of only 47%–50% [25], most series range between 75% to
93%, with the caveat that various deﬁnitions for erectile
dysfunction with and without validated instruments were
used [15, 16, 21]. Even recent series using third generation
systems only report rates of 87% and 88% [29, 31]. One
report by Ellis found that the use of a penile rehabilitation
program improved their potency rates from 41% at 1 year
to 51% at 5 years [18]. Nevertheless, given the high rates
of erectile dysfunction, most reserve cryotherapy for those
patients who are not concerned with potency.
Transient adverse eﬀects such as urinary retention and
rectal pain were minimal in most current series, occurring
in less than 5% [29, 30].
7.Focal Cryotherapy
Although the side eﬀect proﬁle of whole-gland cryotherapy
of the prostate has improved, quality of life issues remain,
particularly the high rates of erectile dysfunction. This is the
result of the proximity of the neurovascular bundles to the
prostatic capsule combined with the necessity of the ice ball
to extend outside of the capsule. The incidence of unilateral
or unifocal small-volume disease and possibility for subtotal
treatment with preservation of the contralateral neurovascu-
lar bundle build the conceptual basis for focal cryotherapy.
Preliminary results from series of low-risk patients show
improvement in postoperative erectile function (65%–89%)
with acceptable bDFS rates using varying deﬁnitions (80%–
95%) [33–36]. However, long-term data are lacking, and
appropriate patient selection and particularly the ability to
identify a truly unilateral or unifocal cancer using current
diagnostic modalities remain to be determined and are
currently under investigation.
8.HIFU
High intensity focused ultrasound (HIFU) is a truly non-
invasive treatment modality in that it requires no incision
or puncture to access the prostate. Instead, high-energy
ultrasound waves produced by a transrectal probe are
absorbed by prostatic tissue converting them to thermal
energy which raises the temperature upwards of 100 degrees
Celsius and results in coagulative necrosis [37]. Damage
is also mediated by cavitation energy resulting from the
interaction between the ultrasound waves and microbubbles
in the sonicated tissue, which also leads to coagulation
necrosis [38]. The ultrasound can be precisely focused on a
tissue target, sparing intervening tissue including the rectal
wall. Moreover, unlike EBRT, HIFU may be repeated if there
is a proven local recurrence. For this reason, there is much
interest in this technology as a minimally invasive method to
ablate prostate lesions with potentially minimal side eﬀects.
Currently, there are two HIFU devices on the market,
the Ablatherm (Edap-Technomed, Lyon, France) and the
Sonablate (Focus Surgery, Indianapolis, IN, USA). Both
devices have undergone several generations of development
to include safety features such as rectal wall cooling and
precise monitoring of rectal temperature. A few diﬀerences
exist in the technologies: while the Ablatherm relies on a
preset treatment algorithm which assumes a constant tissue
threshold for absorption of lethal energy in all patients,
the Sonablate’s system allows for modiﬁcation of energy
exposure to theprostate duringthe procedurebased on grey-
scale changes seen on ultrasound. Both devices are widely
used in Europe and Japan, but are not yet available in the
US outside of clinical trials, which are ongoing.
The ﬁrst reported use of HIFU in the prostate was by
Madersbacherforbenignprostatichypertrophy in1994[39],
followed by its use by Gelet et al. for prostate cancer as
reported in 1996 [40]. Since then, a number of series from
Europe and Japan have reported short-intermediate term
results.
9.SelectionCriteria
Due to focal length of the probe, there is an upper limit to
gland size of 40–50cc, and there should be no calciﬁcations
>1cm as these will obscure ultrasonographic visualization
[41, 42]. In some cases transrectal resection of larger
calciﬁcations may be performed prior to treatment. As with
cryotherapy, most investigators select patients with localized
disease and who either preferred avoiding conventional
treatment orwhose comorbiditiesexcludedmajor surgery or4 Prostate Cancer
EBRT [43]. Mearinin et al. found the best results in patients
with low to moderate risk, with high rates of treatment
failure in the high-risk group [44].
10.Deﬁnitionof TreatmentSuccess
As in the case of cryotherapy, the HIFU literature is plagued
by a lack of consensus on the deﬁnition of biochemical
failure, and therefore, treatment success. Originally, Gelet et
al. used posttreatment PSA < 4.0 with negative biopsy as a
measure for complete response to treatment [40]. This has
evolved from the use of more strict PSA cut-oﬀs, ranging
from 0.2 to 0.5, to most later reports adopting the ASTRO
or Phoenix criteria much like the cryotherapy literature.
However, some argue that because HIFU is an ablative
treatment, it should be held to the stringent standards of
radical prostatectomy (PSA < 0.2), while others suggest
EBRT as the prostate remains in situ after HIFU [45, 46].
In an eﬀort to standardize reporting of outcomes, an
international consortium of HIFU investigators meeting
in Stuttgart, Germany analyzed the various deﬁnitions to
establish their association with future clinical failure, deﬁned
as any record of positive biopsy after HIFU, initiation of
secondary prostate cancer treatment, radiographic evidence
of metastases, or prostate cancer death [47]. They found the
“nadir + 1.2” deﬁnition to be optimal for predicting failure,
deﬁning this as the “Stuttgart deﬁnition”.
As expected and as seen with cryotherapy, nadir PSA has
been shown to be a predictor of subsequent PSA stability
and negative biopsy. Uchida et al. used ASTRO criteria to
show that a nadir PSA of ≤0.2 resulted in 100% bDFS at
3y e a r s[ 42]. This was recently conﬁrmed by Ganzer et al.
using the newly reported Stuttgart deﬁnition, with a PSA ≤
0.2resultingin84%bDFSatmedianfollowupof6years[48].
11.Outcomes
The largest series is reported by Uchida et al. with 517
men, using the Sonablate device [46]. Patients with stage
T1-T3 disease were treated using various generations of the
device, and 66% of the men received neoadjuvant hormonal
therapy for reasons not speciﬁed. bDFS was deﬁned using
Phoenix criteria in this series. At a mean followup of 2 years,
bDFS rates according to D’Amico low-, intermediate-, and
high-risk groupings were 84%, 64%, and 45%, respectively.
483 patients underwent posttreatment biopsy, and negative
biopsy rate was 83%. At the 2010 AUA meeting, Uchida
reported updated results from his series and demonstrated
an improvement in his outcomes using the more recent
technology, with bDFS rates in low-, intermediate-, and
high-risk groups of 93%, 72%, and 58%, compared with
75%, 54%, and 43% in older models [49]. The longest
followup is reported by Blana et al. at a mean of 6.4 years,
usingprototypeandﬁrst-generationAblathermdevices[50].
They treated 140 patients with low-intermediate risk disease
(T1-2 disease, PSA < 15, and Gleason score ≤ 7), deﬁning
treatment failure using the Phoenix criteria, initiation of
salvage therapy, or positive posttreatment biopsy. 16.4% of
patients received neoadjuvant hormones to decrease prostate
volume, and this was discontinued after treatment. Actuarial
disease-free survival at 7 years was 59%, with bDFS of 69%.
Themedian PSAnadir was0.16,andnegativebiopsyratewas
86.4% in 132 patients.
In 2006, Illing et al. proposed a standardized protocol
for treating patients using the Sonablate’s ability to manually
modify treatment based on real-time changes seen on
ultrasound imaging [51]. The group reported on 34 men and
found a signiﬁcantly lowermean PSAnadir, 0.15 versus1.51,
when the visually directed protocol was used as opposed to
an algorithm-based approach.
12.Complications
As with cryotherapy, technological advancements have
decreased morbidity seen with primary HIFU treatment,
including thermocouplers, higher-frequency transducers,
preservation of a 5-mm apical margin to prevent stress
urinary incontinence, and rectal cooling devices [52].
The most dreaded complication is rectouretheral ﬁstula,
but with rectal cooling, this is rarely seen. Thuroﬀ et al.
reported on results from the multicenter Ablatherm trial
[53], with 5 ﬁstulas seen in 402 patients (1.2%). With rectal
cooling, this decreased to 0.5%. In Uchida’sseries, there were
6 ﬁstulas (0.9%), all of which were in patients who had
greater than 2 HIFU sessions [46]. Blana’s series reported 0
ﬁstulas, as did several other investigators [50, 54–56].
Post-HIFU stricture is a bothersome complication that
may require serial dilations or TUIBNC. Uchida reported
16.6% stricture rate in his series, with 3.3% requiring TURP
[46];otherauthorsrecordratesof3.6%to13.6%[50,53,54].
Chaussy reported asigniﬁcant decreasein stricture andurine
retention rate by TURP just before HIFU treatment with the
Ablatherm device [57].
De novo erectile dysfunction is also known to occur, but
as in the cryotherapy literature, rates are diﬃcult to compare
between series due to variable deﬁnitions and lack of use
of validated instruments as well as diﬀerential use of neo-
adjuvanthormonal therapy.Nevertheless,rates ranging from
20% to 43% have been reported [46, 50, 52, 56].
Low-grade incontinence was seen at higher rates in
earlier series, with Thuroﬀ et al. reporting 10.6% with Grade
I and 2.5% Grade II [53], but this has decreased with
next-generation HIFU devices, with grade I incontinence
at 0.8% [46]. Prolonged urinary retention can occur after
HIFU secondary to edema or urethral sloughing, and is
reported to be 0.3 to 13.2% of cases and is usually resolved
after recatheterization. Sloughing occurs in 9%–14% and
is usually self-limited or managed using catheterization but
may rarely require transurethral debridement. Infectious
complications have also been reported at low rates including
UTI and epididymitis [49, 53–56].
13.Vascular-TargetedPhotodynamicTherapy
Vascular-targeted photodynamic therapy (VTP) is an inves-
tigational ablative technology which employs the use ofProstate Cancer 5
a photosensitizing agent, which is taken up by tissue and
produces radical oxygen species upon exposure to light
which results in the destruction of the tissue [58]. Pho-
tosensitizers currently under investigation are WT-09 and
WST-11, which remain conﬁned to the vascular bed [59,
60]. Under ultrasound guidance, light is delivered via
optical ﬁbers inserted into the prostate using a standard
brachytherapy grid, selectively eﬀecting vascular occlusion
and resultant death of prostatic tumors. Thus far, there are
published results from a multi-center collaboration from
Canada examining the safety and eﬃcacy of VTP using
WST-09 in the salvage setting after failed EBRT [61]. They
published results from phase I/II studies which have shown
a 60% complete response as seen on MRI as well as negative
biopsy at 6 months in those subjects receiving the maximal
dose of light energy, with no signiﬁcant change in urinary or
erectile function at 6 months. There are no published studies
of VTP in the primary setting, but a prospective, multicenter
phase I/II trial is currently underway.
14.Conclusion
Although the standard of care for prostate cancer continues
to be surgical extirpation or EBRT, the downward stage
migration resulting from aggressive screening has lead to a
shift in priorities for many patients, with increasing interest
in minimizing the side eﬀects associated with traditional
deﬁnitive treatment. Minimally invasive therapies such as
cryotherapy and HIFU show promise, but continue to be
plagued by a lack of long-term followup and consistency
in outcomes reporting. With maturation of the cryotherapy
and HIFU data sets, treatment-speciﬁc goals of therapy and
a better understanding of side eﬀect proﬁles may become
available, and as investigational therapies such as VTP are
further elucidated, clinicians and patients will hopefully be
able to rely on these minimally invasive ablative therapies as
a deﬁnitive treatment for prostate cancer.
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